Botulinum toxin type-A for the treatment of inverse psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 4, 2008, Pages 431-436

  Zanchi, Malvina ^a   Favot, F ^a   Bizzarini, M ^a   Piai, M ^a   Donini, M ^a   Sedona, P ^a  

^a Ospedale Civile SS Giovanni e Paolo   (Italy)

Author keywords

BOTOX; Botulinumtoxin type A (BoNTA); Inverse psoriasis; Neuroglandular

Indexed keywords

BOTULINUM TOXIN A;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARM; ARTICLE; BODY REGIONS; BREAST; BUTTOCK; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; INGUINAL REGION; INVERSE PSORIASIS; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS; SKIN MACERATION; SYMPTOMATOLOGY; UMBILICUS; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PSORIASIS; TREATMENT OUTCOME;

EID: 41149086799     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02457.x     Document Type: Article

References (16)

1. Beylot C. Clinical aspects of psoriasis. Rev Prat 2004; 54: 19-27.
2. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A; Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-730.
3. Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731-738.
4. Eedy DJ, Johnston CF, Shaw C, Buchanan KD. Neuropeptides in psoriasis: an immunocytochemical and radioimmunoassay study. J Invest Dermatol 1991; 96: 434-438.
5. Vidailhet M. Botulinum toxin in neurology. Rev Med Intern 2005; 26: 531-533.
6. Glogau R. Treatment of hyperidrosis with botulinum toxin. Dermatol Clin 2004; 22: 177-185.
7. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133.
8. Bonifati C, Carducci M, Mussi A, D'auria L, Ameglio F. IL-1 alpha, IL-1 beta and psoriasis: Conflicting results in the literature. Opposite behaviour of the two cytokines in lesional or no-lesional extracts of whole skin. J Biol Regul Homeost Agents 1997; 11: 133-136.
9. Nakkaurinen A, Harvima IT, Aalto ML, Horsmanheimo M. Mast cell tryptase and chymase are potential regulators of neurogenic inflammation in psoriatic skin. Int J Dermatol 1994; 33: 361-366.
10. Lotti T, Hautmann G, Panconesi E. Neuropeptides in skin. J Am Acad Dermatol 1995; 33: 482-496.
11. Staniek V, Doutremepuich J, Schmitt D, Claudy A, Misery L. Expression of substance P receptors in normal and psoriatic skin. Pathobiology 1999; 67: 51-54.
12. Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: Comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003; 149: 718.
13. Orem A, Deger O, Cimsit G, Badahir S. Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis. Clin Chim Acta 1997; 264: 49-56.
14. Pincelli C, Fantini F, Romualdi P et al. Substance P is diminished and VIP is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 1992; 98: 421-427.
15. Farber EM, Rein G, Lanigan SW. Stress and psoriasis. Psychoneuroimmunologic mechanism. Int J Dermatol 1991; 30: 8-12.
16. Konrad H, Karamfilov T, Wollina U. Intracutaneous botulinum toxin A versus ablative therapy for Hailey-Hailey disease - a case report. J Cosmet Laser Ther 2001; 3: 181-184.